Patents for A61P 35 - Antineoplastic agents (221,099)
08/2009
08/26/2009CN101513398A Application of ginkgol in resisting tumors
08/26/2009CN101513397A Anastrozole controlled release patch and preparation method thereof
08/26/2009CN101513395A Taxol double-layer soft capsule oral preparation medicament
08/26/2009CN101513390A Hydrochloric acid boanmycin liposomes and preparation method thereof
08/26/2009CN100532390C Oxygen deficient induction factor1 antisense oligonucleotide and its uses
08/26/2009CN100532381C Antineoplastic compound, medicament composition and use thereof
08/26/2009CN100532380C Heterocyclic compound and anti-malignant-tumor agent containing the same as active ingredient
08/26/2009CN100532376C Use of alkaloid for preparing antineoplastic medicine
08/26/2009CN100531802C Pseudo-type retrovirus vector containing membrane protein having hemagglutinin activity
08/26/2009CN100531801C Polyethylene glycol prodrug of gambogicacid, its preparation method, formulation and use for preparing drug
08/26/2009CN100531798C Combination therapies for B-cell lynphomas comprising administration of anti-CD20 antibody
08/26/2009CN100531796C FGFR agonists
08/26/2009CN100531791C Antineoplastic, anti-cancer drugs
08/26/2009CN100531790C A traditional Chinese medicine composition for treating malignant tumors
08/26/2009CN100531765C Pinellia tuber extract and its preparation process, medicine composition and use
08/26/2009CN100531753C Composition for treating hepatitis c
08/26/2009CN100531742C Antineoplastic super fine particle of amino-polysaccharide, and its preparing method
08/26/2009CN100531720C A long-circulating nanoliposome carrier of hydroxycamptothecine and preparation method thereof
08/26/2009CN100531719C Slow-released injection containing methotrexate synergist
08/26/2009CN100531718C Slow-released injection containing methotrexate synergist
08/26/2009CN100531717C Slow-released anticancer preparation containing methotrexate
08/26/2009CN100531716C Slow-released injection containing methotrexate and its synergist
08/26/2009CN100531715C Slow-released methotrexate injection
08/26/2009CN100531712C Dasatini sustained-release implants for treating entity tumor
08/26/2009CN100531711C Erlotinib sustained-release implants for treating entity tumor
08/25/2009US7579479 Modulators of blood glucose levels, triglyceride levels, insulin levels and non-esterified fatty acid (NEFA) levels; hypoglycemia
08/25/2009US7579467 N-phenyl-2-pyrimidine-amine derivatives
08/25/2009US7579452 immunogenic composition comprising a polynucleotide encoding a nonfunctional mutant Brother of Regulator of Imprinted Sites (BORIS) protein; vaccine against cancer; biodrug delivery of specific nucleic acid
08/25/2009US7579445 Reagents and methods for inducing an immune response to prostate specific antigen
08/25/2009US7579439 Modulation of IL-2- and IL-15-mediated T cell responses
08/25/2009US7579435 Somatostatin-dopamine chimeric analogs
08/25/2009US7579376 N-geranoyltyrosine and N-geranoylcycteine as excellant antitumor and anticarcinogenic agents
08/25/2009US7579373 Targeted bisplatinum polyamines as pro-drugs: selective release of platinum
08/25/2009US7579366 Epothilone derivatives and their synthesis and use
08/25/2009US7579365 For therapy of oncoses
08/25/2009US7579357 Antidiabetic agents; obesity; controlling appetite
08/25/2009US7579346 Carboxamides
08/25/2009US7579344 Pyrimidine derivatives possessing cell-cycle inhibitors activity
08/25/2009US7579337 Analogs of benzoquinone-containing ansamycins and methods of use thereof
08/25/2009US7579336 Pharmaceutical composition comprising temozolomide ester
08/25/2009US7579330 Methods of treating various cancers using melanoma differentiation associated protein-7
08/25/2009US7579327 Isolated polynucleotide sequences; controlling neovasculization; cell growth regulators
08/25/2009US7579323 Analogs of hemiasterlin wherein the indole moiety of hemiasterlin has been deleted or replaced demonstrate potent anti-mitotic and cytotoxic activity; may be useful in treatment of colon, breast, lung cancers
08/25/2009US7579320 Inhibitors of apoptosis proteins (IAP); antiproliferative agents; anticancer agents
08/25/2009US7579170 Method for preparing monoclonal antibodies capable of activating effector cells expressing FCγRIII
08/25/2009US7579023 Method of preparation and composition of a water soluble extract of the bioactive component of the plant species Uncaria for enhancing immune, anti-inflammatory, anti-tumor and DNA repair processes of warm blooded animals
08/25/2009US7579009 a whole cell of a bacterium from the genera Rhodococcus, Gordonia, Nocardia, Dietzia, Tsukamurella and Nocardioides and at least one antigen or antigenic determinant; tuberculosis and leishmaniasis; vaccines
08/25/2009US7579001 Antagonists of TWEAK and of TWEAK receptor and their use to treat immunological disorders
08/25/2009CA2414967C Valproic acid and derivatives thereof as histone deacetylase inhibitors
08/25/2009CA2405172C Alpha,beta-unsaturated sulfones for treating proliferative disorders
08/25/2009CA2385302C Receptor proteins specifically recognizing bacterial dna
08/25/2009CA2382521C Oligonucleotide n3'.fwdarw.p5' thiophosphoramidates: their synthesis and use
08/25/2009CA2366932C Cyclic protein tyrosine kinase inhibitors
08/25/2009CA2269246C Substituted tricyclics
08/25/2009CA2099541C Cyclic adhesion inhibitors
08/20/2009WO2009103076A1 Methods and compositions for enhancing the efficacy of rtk inhibitors
08/20/2009WO2009103032A1 Pyrimidine-2-amine compounds and their use as inhibitors of jak kinases
08/20/2009WO2009102986A1 Treatment of adenocarcinoma expressing lkb1 with mtor inhibitor in combination with cox1 inhibitor
08/20/2009WO2009102909A2 Anti-cancer vaccines
08/20/2009WO2009102880A2 Structure and bioactivity of the polysaccharides and oligomers in medicinal plant dendrobium huoshanense
08/20/2009WO2009102808A2 Doxorubicin adjuvants to reduce toxicity and methods for using the same
08/20/2009WO2009102778A1 Amorphous polymorph of bazedoxifene acetate
08/20/2009WO2009102707A2 Substituted oxazaphosphorines
08/20/2009WO2009102497A2 Genetic regulation of host defense mechanisms by mucosal exposure to natural interferon alpha species
08/20/2009WO2009102496A2 Selective agonist of toll-like receptor 3
08/20/2009WO2009102465A2 Continuous cell programming devices
08/20/2009WO2009102367A2 Tight junction protein modulators and uses thereof
08/20/2009WO2009102240A2 Medicinal agent for treating oncological diseases
08/20/2009WO2009102239A1 Medicinal agent for treating oncological diseases
08/20/2009WO2009102050A1 Intestinal immune system stimulator
08/20/2009WO2009102008A1 Low-molecular-weight substance derived from maitake mushroom and having immunostimulating activity and anti-tumor activity
08/20/2009WO2009101968A1 Anti-adam-15 antibodies and utilization of the same
08/20/2009WO2009101812A1 Glutamic acid transporter inhibitor
08/20/2009WO2009101533A1 Treatment of metastatic stage prostate cancer with degarelix
08/20/2009WO2009101530A1 Method of treating prostate cancer with the gnrh antagonist degarelix
08/20/2009WO2009101263A2 Soluble complexes of curcumin
08/20/2009WO2009101012A1 Methods for treating and preventing brain tumors based on bone morphogenetic proteins
08/20/2009WO2009100955A1 Antisense rna targeting cxcr4
08/20/2009WO2009100929A1 Pharmaceutical compositions comprising n-[2-(diethylamino)ethyl]-5-[(5-fluoro-1,2- dihydro-2-oxo-3h-indol-3-ylidene)methyl]-2,4-dimethyl-1h-pyrrole-3-carboxamide
08/20/2009WO2009100691A1 Polymorphic form ( iii ) of the adamantylamino- platinum (iv) complex la- 12
08/20/2009WO2009100690A1 Amourphous form of the adamantylamino-platinum ( iv) complexla-12
08/20/2009WO2009100689A1 Polymorphic form ( ii ) of adamantylamino- platinum ( iv) complex la-12
08/20/2009WO2009100688A1 Polymorphic form ( i ) of the adamantylamino-platinum (iv) complex la-12
08/20/2009WO2009100656A1 2-methylene-5-substituted methylene cyclopentanone derivatives and use thereof
08/20/2009WO2009100655A1 The aromatic ring triazine derivatives and the uses thereof
08/20/2009WO2009100536A1 Inhibitors of kinase activity with 1,2-di-cyclyl substituted alkyne structures
08/20/2009WO2009100530A1 Uses of modified elr-cxc chemokine g31p
08/20/2009WO2009082641A3 Compositions and methods for treating diseases associated with angiogenesis and inflammation
08/20/2009WO2009081105A3 Quinoxaline and quinoline derivatives as kinase inhibitors
08/20/2009WO2009074749A3 Nicotinamide derivatives, preparation thereof and therapeutic use thereof
08/20/2009WO2009073527A3 Methods and compositions for reducing activity of the atrial natriuretic peptide receptor and for treatment of diseases
08/20/2009WO2009072831A3 Novel use of flj25416 gene
08/20/2009WO2009070294A3 Inhibition of macrophage-stimulating protein receptor (ron) and methods of treatment thereof
08/20/2009WO2009053654A3 Gemcitabine phosphoester prodrugs as anticancer agents
08/20/2009WO2009046872A3 Use of a peptide as a therapeutic agent
08/20/2009WO2009033808A3 Use of a peptide as a therapeutic agent
08/20/2009WO2009033789A3 Use of a peptide as a therapeutic agent
08/20/2009WO2009033754A3 Use of a peptide as a therapeutic agent
08/20/2009WO2009025876A3 Crystalline forms of erlotinib hcl and formulations thereof
08/20/2009WO2009012156A3 Treatments and diagnostics for cancer, inflammatory disorders and autoimmune disorders